Last reviewed · How we verify
Continuous indomethacin
Continuous indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain.
Continuous indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain. Used for Patent ductus arteriosus (PDA) closure in premature infants, Inflammatory conditions requiring sustained anti-inflammatory therapy.
At a glance
| Generic name | Continuous indomethacin |
|---|---|
| Sponsor | Shaare Zedek Medical Center |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | COX-1, COX-2 |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Pain Management / Neonatology |
| Phase | Phase 3 |
Mechanism of action
Indomethacin works by blocking COX-1 and COX-2 enzymes, which are responsible for producing prostaglandins that mediate inflammation, pain, and fever. The continuous formulation is designed to provide sustained drug levels, potentially improving efficacy or tolerability compared to standard dosing. This mechanism makes it useful in conditions where sustained anti-inflammatory activity is therapeutically beneficial.
Approved indications
- Patent ductus arteriosus (PDA) closure in premature infants
- Inflammatory conditions requiring sustained anti-inflammatory therapy
Common side effects
- Gastrointestinal bleeding or ulceration
- Renal impairment
- Cardiovascular events
- Necrotizing enterocolitis (in neonates)
Key clinical trials
- Study Comparing Transobturator Cystocele vs. Anterior Vaginal RepairS (NA)
- Ketorolac Applied by Continuous IV Infusion for Treatment of Moderately Severe Postoperative Pain Following Bunionectomy (PHASE3)
- Initial Pain Management in Pediatric Pancreatitis: Opioid vs. Non-Opioid (PHASE2)
- Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC) (PHASE1)
- T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers (PHASE1)
- Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection (PHASE3)
- Autonomic Control of the Circulation and VDR (EARLY_PHASE1)
- Continuous Infusion Versus Bolus Dosing for Pain Control After Pediatric Cardiothoracic Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Continuous indomethacin CI brief — competitive landscape report
- Continuous indomethacin updates RSS · CI watch RSS
- Shaare Zedek Medical Center portfolio CI